Fig. 6.
Myricetin reduces the activity of SEVI in enhancing HIV-1 infection. CEMx174 5.25M7 cells infected by HIV-1 SF162 in the presence or absence of SEVI (100 μg/ml) and myricetin (50 μg/ml) were imaged by fluorescence microscopy (a) and flow cytometric analysis (b). c The percentages of GFP+ CEMx174 5.25 M7 cells from multiple experiments. d Cell viability assay of CEMx174 5.25 M7 and TZM-bl cells with or without SEVI (100 or 50 μg/ml) or/and myricetin (50 μg/ml). SEVI (50 μg/ml) was incubated with myricetin at various concentrations (50, 25, 12.5, 6.25, 3.13, 1.56, 0.78 and 0.39 μg/ml). The mixtures were centrifuged to remove soluble myricetin. The pellets were resuspended in the original volume of medium and mixed with CCR5-tropic HIV-1SF162 (e) or CXCR4-tropic HIV-1NL4-3 (f). The luciferase activities of the cultures were measured at 72 h post-infection. Average values (± SD) were calculated from triplicate measurements; the data shown represent one representative trial of three independent experiments. One-way ANOVA with Dunnett’s post hoc multiple comparisons test was used to statistically analyze differences between samples containing SEVI alone and samples containing SEVI and myricetin (*p < 0.05; **p < 0.01, ***p < 0.001)